Prof. Eva Corey

University of Washington, USA

Email: [email protected]

Qualifications

1989 Ph.D., Czechoslovak Academy of Sciences, Czechoslovakia

1987 M.Sc., Charles University, Czechoslovakia

1985 B.Sc., Charles University, Czechoslovakia

Publications (selected)

1. Sekar, A., Selvadurai, B.R., Chatterjee, R., Pal, L., Verma, A., Belugali Nataraj, N. and others. TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens. EMBO Molecular Medicine, 1-36, 2026.
2. Guersetti, F.E., Mojtahedzadeh, B., Xie, D., Koohbor, S., Corey, E., Haffner, M.E. and others. Abstract LB244: Osteosclerosis is associated to low anaplastic histological patterns in prostate cancer bone metastasis. Cancer Research, 86(8_Supplement), LB244, 2026.
3. Jeon, H.Y., Khadka, S., Pornour, M., Ryu, H., Chen, H., Hussain, A., Lam, H.M. and others. BPTF regulates androgen receptor activity in prostate cancer. Cancer Research, 86(7_Supplement), 7247, 2026.
4. Lin, K.M., Seidl, A., Waldman, T., Li, X., Corey, E., Sowalsky, A.G. and Kotula, L. Alternative splicing of ABI1 by enzalutamide treatment drives tumor plasticity in prostate cancer. Cancer Research, 86(7_Supplement), 4763, 2026.
5. Hartono, A.B., Hwang, H.J., Paparaju, S., Liu, S., Brooks, J.D., Corey, E. and others. CDC7 is a targetable regulator of advanced prostate cancer. Scientific Reports, 2025.
6. Tarun, M.T.I., Ebrahim, H.Y., Dawud, D., Elmageed, Z.Y.A., Corey, E. and El Sayed, K.A. The Olive Phenolic S–(–)–Oleocanthal as a Novel Intervention for Neuroendocrine Prostate Cancers: Therapeutic and Molecular Insights. Nutrients, 17(24), 3947, 2025.
7. Jeon, H.Y., Khadka, S., Pornour, M., Ryu, H., Chen, H., Hussain, A., Lam, H.M. and others. BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction. Nature Communications, 2025.
8. Ma, F., Chen, S., Cecchi, L., Ersoy-Fazlioglu, B., Russo, J.W., Arai, S., Awad, S. and others. Androgen deprivation–mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion. The Journal of Clinical Investigation, 135(23), 2025.
9. Westaby, D., Jiménez-Vacas, J.M., Figueiredo, I., Rekowski, J., Pettinger, C. and others. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. The Journal of Clinical Investigation, 134(18), 2024.
10. Xu, P., Yang, J.C., Chen, B., Ning, S., Zhang, X., Wang, L., Nip, C., Shen, Y. and others. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature Communications, 15(1), 6626, 2024.
11. Cheng, S., Li, L., Yeh, Y., Shi, Y., Franco, O., Corey, E. and Yu, X. Unveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis. NPJ Precision Oncology, 8(1), 171, 2024.
12. Yin, J.J., Daryanani, A., Lu, F., Ku, A.T., Bright, J.R., Alilin, A.N.S., Bowman, J. and others. Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis. The Prostate, 84(11):1033-1046, 2024.
13. Sugawara, T., Nevedomskaya, E., Heller, S., Böhme, A., Lesche, R. and others. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Molecular Oncology, 18(3):726-742, 2024.
14. Franceschini, G.M., Quaini, O., Mizuno, K., Orlando, F., Ciani, Y., Ku, S.Y. and others. Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discovery, 14(3):424-445, 2024.
15. Chen, C.C., Tran, W., Song, K., Sugimoto, T., Obusan, M.B., Wang, L., Sheu, K.M. and others. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell, 41(12):2066-2082.e9, 2023.
16. Corey, E. Therapeutic Targeting of Neuroendocrine Prostate Cancer. 2023.
17. Sandoval, G.J., Centore, R.C., Topal, S., Lahr, D., Elliott, G.N., Gandevia, H. and others. Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer. Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, 2023.
18. Giafaglione, J.M., Crowell, P.D., Delcourt, A.M.L., Hashimoto, T., Ha, S.M. and others. Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment. Nature Cell Biology, 25(12):1821-1832, 2023.
19. Zivanovic, A., Miller, J.T., Munro, S.A., Knutson, T.P., Li, Y., Passow, C.N. and others. Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. NAR Cancer, 5(3), zcad045, 2023.
20. Nyquist, M.D., Coleman, I.M., Lucas, J.M., Li, D., Hanratty, B., Meade, H. and others. Supraphysiological androgens promote the tumor suppressive activity of the androgen receptor through cMYC repression and recruitment of the DREAM complex. Cancer Research, 83(17):2938-2951, 2023.
21. Schuster, S.L., Arora, S., Wladyka, C.L., Itagi, P., Corey, L., Young, D. and others. Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3′ untranslated region mutations. Cell Reports, 42(8), 2023.
22. Gritsina, G., Fong, K., Lu, X., Lin, Z., Xie, W., Agarwal, S., Lin, D., Schiltz, G.E. and others. Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. The Journal of Clinical Investigation, 133(15), 2023.
23. Zaalberg, A., Minnee, E., Mayayo-Peralta, I., Schuurman, K., Gregoricchio, S. and others. A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator. bioRxiv, 2023.

Personal Details

WoS Researcher ID: GBM-5995-2022

https://urology.uw.edu/people/faculty/eva-corey

https://scholar.google.com/citations?user=OTbMBJl7SyEC&hl=en

https://www.researchgate.net/profile/Eva-Corey